These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39092804)

  • 21. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
    Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
    Ushijima K; Tsuda N; Yamagami W; Mitsuhashi A; Mikami M; Yaegashi N; Enomoto T
    J Gynecol Oncol; 2023 May; 34(3):e38. PubMed ID: 36659833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.
    Kataoka H; Mori T; Yamamoto T; Sawada M; Kuroboshi H; Tatsumi H; Iwasaku K; Kitawaki J
    Eur J Gynaecol Oncol; 2014; 35(1):11-5. PubMed ID: 24654454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
    He YJ; Wang YQ; Tang HR; He M; Rao Y; Zhou R; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):21-28. PubMed ID: 32074769
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
    Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
    Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
    [No Abstract]   [Full Text] [Related]  

  • 29. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
    Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
    Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study.
    Oishi M; Kasuga Y; Fukuma Y; Hamuro A; Tamai J; Tanaka Y; Hasegawa K; Yoshimura T; Ikenoue S; Ochiai D; Yamagami W; Tanaka M
    Int J Clin Oncol; 2023 Apr; 28(4):587-591. PubMed ID: 36662363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
    Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
    Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
    Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
    Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
    Wang Y; Zhou R; Wang H; Liu H; Wang J
    Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
    Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
    J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial).
    Sakai K; Yamagami W; Sato Y; Susumu N; Yokoyama Y; Takehara K; Mandai M; Okamoto A
    J Gynecol Oncol; 2024 Nov; 35(6):e106. PubMed ID: 38789396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome.
    Wang L; Luo X; Wang Q; Lv Q; Wu P; Liu W; Chen X
    J Gynecol Oncol; 2021 Sep; 32(5):e70. PubMed ID: 34132069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
    Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
    Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma.
    Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Kanao H; Kato K; Utsugi K; Takeshima N
    Jpn J Clin Oncol; 2018 Mar; 48(3):255-258. PubMed ID: 29351618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.